---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-26-000066"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2026-08-19T20:11:54+00:00"
generated_at: "2026-08-19T20:13:06.985735+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aurinia settles Teva patent litigation; generic voclosporin launch no earlier than Dec 7, 2036

## Summary
- Settlement with Teva resolves generic patent litigation over Teva's ANDA for 7.9 mg voclosporin oral capsules.
- Teva stipulates U.S. Patent Nos. 10,286,036 and 11,622,991 valid, enforceable, and infringed; patents expire December 2037.
- Teva may launch generic voclosporin no earlier than Dec 7, 2036, subject to FDA approval and certain defined contingencies.
- Aurinia's patent actions continue against DifGen, Dr. Reddy's, Galenicum, Hikma, Lotus, Sandoz, and Zydus in District of New Jersey.

## SEC filing metadata
- accession: 0001600620-26-000066
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2026-08-19T20:11:54+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000066/0001600620-26-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000066/auph-20260819.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-26-000066
- JSON: https://secwatch.observer/filing/0001600620-26-000066.json
- Plain text: https://secwatch.observer/filing/0001600620-26-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.